Amicus Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Amicus Therapeutics has a total shareholder equity of $132.5M and total debt of $388.9M, which brings its debt-to-equity ratio to 293.5%. Its total assets and total liabilities are $749.5M and $617.0M respectively.
Key information
293.5%
Debt to equity ratio
US$388.94m
Debt
Interest coverage ratio | n/a |
Cash | US$260.06m |
Equity | US$132.52m |
Total liabilities | US$616.96m |
Total assets | US$749.48m |
Recent financial health updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Recent updates
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Financial Position Analysis
Short Term Liabilities: FOLD's short term assets ($461.7M) exceed its short term liabilities ($168.1M).
Long Term Liabilities: FOLD's short term assets ($461.7M) exceed its long term liabilities ($448.9M).
Debt to Equity History and Analysis
Debt Level: FOLD's net debt to equity ratio (97.2%) is considered high.
Reducing Debt: FOLD's debt to equity ratio has increased from 24.8% to 293.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FOLD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FOLD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.